Down syndrome and Alzheimer's disease

Common pathways, common goals

Dean Hartley, Thomas Blumenthal, Maria Carrillo, Gilbert DiPaolo, Lucille Esralew, Katheleen Gardiner, Ann Charlotte Granholm, Khalid Iqbal, Michael Krams, Cynthia Lemere, Ira Lott, William Mobley, Seth Ness, Ralph Nixon, Huntington Potter, Roger H Reeves, Marwan Sabbagh, Wayne P Silverman, Benjamin Tycko, Michelle Whitten & 1 others Thomas Wisniewski

Research output: Contribution to journalArticle

Abstract

In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.

Original languageEnglish (US)
Pages (from-to)700-709
Number of pages10
JournalAlzheimer's and Dementia
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Down Syndrome
Alzheimer Disease
Education
Life Expectancy
Dementia
Clinical Trials
Pathology
Research
Pharmaceutical Preparations

Keywords

  • ADNI
  • Alzheimer's disease
  • Amyloid precursor protein
  • Animal models
  • Beta-amyloid
  • Biomarkers
  • Clinical trials
  • Cognitive assessment
  • Dementia
  • Down syndrome
  • Drug discovery
  • DS-Connect
  • Neuroimaging
  • Neuroinflammation
  • Tau
  • Trisomy 21
  • Ts65Dn
  • Workshop

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., ... Wisniewski, T. (2015). Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimer's and Dementia, 11(6), 700-709. https://doi.org/10.1016/j.jalz.2014.10.007

Down syndrome and Alzheimer's disease : Common pathways, common goals. / Hartley, Dean; Blumenthal, Thomas; Carrillo, Maria; DiPaolo, Gilbert; Esralew, Lucille; Gardiner, Katheleen; Granholm, Ann Charlotte; Iqbal, Khalid; Krams, Michael; Lemere, Cynthia; Lott, Ira; Mobley, William; Ness, Seth; Nixon, Ralph; Potter, Huntington; Reeves, Roger H; Sabbagh, Marwan; Silverman, Wayne P; Tycko, Benjamin; Whitten, Michelle; Wisniewski, Thomas.

In: Alzheimer's and Dementia, Vol. 11, No. 6, 01.06.2015, p. 700-709.

Research output: Contribution to journalArticle

Hartley, D, Blumenthal, T, Carrillo, M, DiPaolo, G, Esralew, L, Gardiner, K, Granholm, AC, Iqbal, K, Krams, M, Lemere, C, Lott, I, Mobley, W, Ness, S, Nixon, R, Potter, H, Reeves, RH, Sabbagh, M, Silverman, WP, Tycko, B, Whitten, M & Wisniewski, T 2015, 'Down syndrome and Alzheimer's disease: Common pathways, common goals', Alzheimer's and Dementia, vol. 11, no. 6, pp. 700-709. https://doi.org/10.1016/j.jalz.2014.10.007
Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimer's and Dementia. 2015 Jun 1;11(6):700-709. https://doi.org/10.1016/j.jalz.2014.10.007
Hartley, Dean ; Blumenthal, Thomas ; Carrillo, Maria ; DiPaolo, Gilbert ; Esralew, Lucille ; Gardiner, Katheleen ; Granholm, Ann Charlotte ; Iqbal, Khalid ; Krams, Michael ; Lemere, Cynthia ; Lott, Ira ; Mobley, William ; Ness, Seth ; Nixon, Ralph ; Potter, Huntington ; Reeves, Roger H ; Sabbagh, Marwan ; Silverman, Wayne P ; Tycko, Benjamin ; Whitten, Michelle ; Wisniewski, Thomas. / Down syndrome and Alzheimer's disease : Common pathways, common goals. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 6. pp. 700-709.
@article{de6358bfa1a64cb9a7309d35b0f2b140,
title = "Down syndrome and Alzheimer's disease: Common pathways, common goals",
abstract = "In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70{\%} will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.",
keywords = "ADNI, Alzheimer's disease, Amyloid precursor protein, Animal models, Beta-amyloid, Biomarkers, Clinical trials, Cognitive assessment, Dementia, Down syndrome, Drug discovery, DS-Connect, Neuroimaging, Neuroinflammation, Tau, Trisomy 21, Ts65Dn, Workshop",
author = "Dean Hartley and Thomas Blumenthal and Maria Carrillo and Gilbert DiPaolo and Lucille Esralew and Katheleen Gardiner and Granholm, {Ann Charlotte} and Khalid Iqbal and Michael Krams and Cynthia Lemere and Ira Lott and William Mobley and Seth Ness and Ralph Nixon and Huntington Potter and Reeves, {Roger H} and Marwan Sabbagh and Silverman, {Wayne P} and Benjamin Tycko and Michelle Whitten and Thomas Wisniewski",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jalz.2014.10.007",
language = "English (US)",
volume = "11",
pages = "700--709",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Down syndrome and Alzheimer's disease

T2 - Common pathways, common goals

AU - Hartley, Dean

AU - Blumenthal, Thomas

AU - Carrillo, Maria

AU - DiPaolo, Gilbert

AU - Esralew, Lucille

AU - Gardiner, Katheleen

AU - Granholm, Ann Charlotte

AU - Iqbal, Khalid

AU - Krams, Michael

AU - Lemere, Cynthia

AU - Lott, Ira

AU - Mobley, William

AU - Ness, Seth

AU - Nixon, Ralph

AU - Potter, Huntington

AU - Reeves, Roger H

AU - Sabbagh, Marwan

AU - Silverman, Wayne P

AU - Tycko, Benjamin

AU - Whitten, Michelle

AU - Wisniewski, Thomas

PY - 2015/6/1

Y1 - 2015/6/1

N2 - In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.

AB - In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.

KW - ADNI

KW - Alzheimer's disease

KW - Amyloid precursor protein

KW - Animal models

KW - Beta-amyloid

KW - Biomarkers

KW - Clinical trials

KW - Cognitive assessment

KW - Dementia

KW - Down syndrome

KW - Drug discovery

KW - DS-Connect

KW - Neuroimaging

KW - Neuroinflammation

KW - Tau

KW - Trisomy 21

KW - Ts65Dn

KW - Workshop

UR - http://www.scopus.com/inward/record.url?scp=84931070277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931070277&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.10.007

DO - 10.1016/j.jalz.2014.10.007

M3 - Article

VL - 11

SP - 700

EP - 709

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 6

ER -